Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I4DQ
|
||||
| Former ID |
DAP000359
|
||||
| Drug Name |
Alprostadil
|
||||
| Synonyms |
Alista; Alprostadilum; Befar; Caverject; Edex; FemLife; Femprox; Muse; Prink; Prostavasin; RayVa; Sugiran; Topiglan; Viridal; Vitaros; Prostin VR; Prostin VR Pediatric; Alprostadil Prostoglandin E1; MR 256; PGE1; PGE1 Oligomer; Prostaglandin E1; Alprox-TD; BML1-F06; Befar (TN); Caverject (TN); Edex (TN); HEI-507; L-Prostaglandin E1; MR-256; Muse (TN); Prink (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10:F52.2, N48.4] | Approved | [1], [2] | ||
| Therapeutic Class |
Vasodilator Agents
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H34O5
|
||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
|
||||
| InChIKey |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
||||
| CAS Number |
CAS 745-65-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7312, 3139926, 4266050, 7847248, 7978676, 8143220, 8616376, 12013405, 14901054, 14901056, 24887977, 24890439, 24898661, 24898855, 24898994, 26719695, 26752225, 26752226, 39289772, 46386879, 46386882, 46387002, 47216549, 47515087, 47515088, 47810514, 47959471, 48110217, 48184750, 48415538, 49681576, 49699251, 50104916, 50104917, 53790811, 57357853, 57654538, 77812073, 85789478, 91702047, 92126041, 92308647, 92309224, 92309904, 92712130, 93166905, 99300818, 99302336, 103171219, 103914567
|
||||
| ChEBI ID |
ChEBI:15544
|
||||
| SuperDrug ATC ID |
C01EA01; G04BE01
|
||||
| SuperDrug CAS ID |
cas=000745653
|
||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Modulator | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1882). | ||||
| REF 3 | Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.